RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization

Antonina Germano, Ida Rapa, Marco Volante, Silvia De Francia, Cristina Migliore, Alfredo Berruti, Mauro Papotti, Massimo Terzolo

Research output: Contribution to journalArticle

Abstract

The anti-proliferative activity of mitotane (o,p'DDD) in adrenocortical cancer is mediated by its metabolites o,p'DDE and o,p'DDA. We previously demonstrated a functional link between ribonucleotide reductase M1(RRM1) expression and o,p'DDD activity, but the mechanism is unknown. In this study we assessed the impact of RRM1 on the bioavailability and cytotoxic activity of o,p'DDD, o,p'DDE and o,p'DDA in SW13 and H295R cells. In H295R cells, mitotane and its metabolites showed a similar cytotoxicity and RRM1 expression was not influenced by any drug. In SW13 cells, o,p'DDA only showed a cytotoxic activity and did not modify RRM1 expression, whereas the lack of sensitivity to o,p'DDE was associated to RRM1 gene up-modulation, as already demonstrated for o,p'DDD. RRM1 silencing in SW13 cells increased the intracellular transformation of mitotane into o,p'DDE and o,p'DDA. These data demonstrate that RRM1 gene interferes with mitotane metabolism in adrenocortical cancer cells, as a possible mechanisms of drug resistance.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalMolecular and Cellular Endocrinology
Volume401
DOIs
Publication statusPublished - Feb 5 2015

Fingerprint

Adrenal Gland Neoplasms
Mitotane
Ribonucleotide Reductases
Cells
Dichlorodiphenyl Dichloroethylene
Adrenal Cortex Neoplasms
Metabolites
Genes
Cytotoxicity
Drug Resistance
Metabolism
Pharmaceutical Preparations
Biological Availability
Modulation

Keywords

  • Adrenocortical cancer
  • Cell lines
  • Metabolites
  • Mitotane
  • RRMI

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology
  • Biochemistry
  • Medicine(all)

Cite this

RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. / Germano, Antonina; Rapa, Ida; Volante, Marco; De Francia, Silvia; Migliore, Cristina; Berruti, Alfredo; Papotti, Mauro; Terzolo, Massimo.

In: Molecular and Cellular Endocrinology, Vol. 401, 05.02.2015, p. 105-110.

Research output: Contribution to journalArticle

Germano, Antonina ; Rapa, Ida ; Volante, Marco ; De Francia, Silvia ; Migliore, Cristina ; Berruti, Alfredo ; Papotti, Mauro ; Terzolo, Massimo. / RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. In: Molecular and Cellular Endocrinology. 2015 ; Vol. 401. pp. 105-110.
@article{d182628b2f3f4d08998b3407181e33cf,
title = "RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization",
abstract = "The anti-proliferative activity of mitotane (o,p'DDD) in adrenocortical cancer is mediated by its metabolites o,p'DDE and o,p'DDA. We previously demonstrated a functional link between ribonucleotide reductase M1(RRM1) expression and o,p'DDD activity, but the mechanism is unknown. In this study we assessed the impact of RRM1 on the bioavailability and cytotoxic activity of o,p'DDD, o,p'DDE and o,p'DDA in SW13 and H295R cells. In H295R cells, mitotane and its metabolites showed a similar cytotoxicity and RRM1 expression was not influenced by any drug. In SW13 cells, o,p'DDA only showed a cytotoxic activity and did not modify RRM1 expression, whereas the lack of sensitivity to o,p'DDE was associated to RRM1 gene up-modulation, as already demonstrated for o,p'DDD. RRM1 silencing in SW13 cells increased the intracellular transformation of mitotane into o,p'DDE and o,p'DDA. These data demonstrate that RRM1 gene interferes with mitotane metabolism in adrenocortical cancer cells, as a possible mechanisms of drug resistance.",
keywords = "Adrenocortical cancer, Cell lines, Metabolites, Mitotane, RRMI",
author = "Antonina Germano and Ida Rapa and Marco Volante and {De Francia}, Silvia and Cristina Migliore and Alfredo Berruti and Mauro Papotti and Massimo Terzolo",
year = "2015",
month = "2",
day = "5",
doi = "10.1016/j.mce.2014.11.027",
language = "English",
volume = "401",
pages = "105--110",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization

AU - Germano, Antonina

AU - Rapa, Ida

AU - Volante, Marco

AU - De Francia, Silvia

AU - Migliore, Cristina

AU - Berruti, Alfredo

AU - Papotti, Mauro

AU - Terzolo, Massimo

PY - 2015/2/5

Y1 - 2015/2/5

N2 - The anti-proliferative activity of mitotane (o,p'DDD) in adrenocortical cancer is mediated by its metabolites o,p'DDE and o,p'DDA. We previously demonstrated a functional link between ribonucleotide reductase M1(RRM1) expression and o,p'DDD activity, but the mechanism is unknown. In this study we assessed the impact of RRM1 on the bioavailability and cytotoxic activity of o,p'DDD, o,p'DDE and o,p'DDA in SW13 and H295R cells. In H295R cells, mitotane and its metabolites showed a similar cytotoxicity and RRM1 expression was not influenced by any drug. In SW13 cells, o,p'DDA only showed a cytotoxic activity and did not modify RRM1 expression, whereas the lack of sensitivity to o,p'DDE was associated to RRM1 gene up-modulation, as already demonstrated for o,p'DDD. RRM1 silencing in SW13 cells increased the intracellular transformation of mitotane into o,p'DDE and o,p'DDA. These data demonstrate that RRM1 gene interferes with mitotane metabolism in adrenocortical cancer cells, as a possible mechanisms of drug resistance.

AB - The anti-proliferative activity of mitotane (o,p'DDD) in adrenocortical cancer is mediated by its metabolites o,p'DDE and o,p'DDA. We previously demonstrated a functional link between ribonucleotide reductase M1(RRM1) expression and o,p'DDD activity, but the mechanism is unknown. In this study we assessed the impact of RRM1 on the bioavailability and cytotoxic activity of o,p'DDD, o,p'DDE and o,p'DDA in SW13 and H295R cells. In H295R cells, mitotane and its metabolites showed a similar cytotoxicity and RRM1 expression was not influenced by any drug. In SW13 cells, o,p'DDA only showed a cytotoxic activity and did not modify RRM1 expression, whereas the lack of sensitivity to o,p'DDE was associated to RRM1 gene up-modulation, as already demonstrated for o,p'DDD. RRM1 silencing in SW13 cells increased the intracellular transformation of mitotane into o,p'DDE and o,p'DDA. These data demonstrate that RRM1 gene interferes with mitotane metabolism in adrenocortical cancer cells, as a possible mechanisms of drug resistance.

KW - Adrenocortical cancer

KW - Cell lines

KW - Metabolites

KW - Mitotane

KW - RRMI

UR - http://www.scopus.com/inward/record.url?scp=84919884649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919884649&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2014.11.027

DO - 10.1016/j.mce.2014.11.027

M3 - Article

C2 - 25497672

AN - SCOPUS:84919884649

VL - 401

SP - 105

EP - 110

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

ER -